Valproate semisodium appears to accelerate brain volume loss in patients with Alzheimer's disease
- PDF / 136,558 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 91 Downloads / 126 Views
1
■ Valproate semisodium appears to accelerate brain volume loss in patients with Alzheimer’s disease (AD), found US-based researchers in their recent study.* A subset of 88 AD patients enrolled in a 24-month trial had eligible MRI scans (n = 45 for placebo; 43 for valproate semisodium). At 12 months, compared with placebo, valproate semisodium recipients showed a greater decline from baseline in hippocampal and brain volumes, and greater ventricular expansion (p < 0.001). Moreover, MMSE** scores demonstrated a more rapid decline from baseline to month 12 in the valproate semisodium group versus the placebo group (3.9 to 4.0 vs 2.0 to 4.3). The researchers note that it is unclear if these observed outcomes result from "direct drug effects . . . or whether these effects are reversible or clinically relevant". * presented at the 2010 International Conference on Alzheimer’s Disease and Related Disorders ** Mini-Mental State Examination Fleisher AS, et al. Brain volume changes with divalproex sodium in Alzheimers disease. 2010 International Conference on Alzheimer’s Disease and Related Disorders : abstr. P1-433, 10 Jul 2010. Available from: URL: 803027902 http://www.alz.org/icad
0114-9954/10/1311-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 24 Jul 2010 No. 1311
Data Loading...
